Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 34.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,119 shares of the company’s stock after buying an additional 4,093 shares during the quarter. HighTower Advisors LLC’s holdings in Elanco Animal Health were worth $237,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ELAN. Benjamin F. Edwards & Company Inc. grew its position in Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $29,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health in the second quarter valued at $32,000. AM Squared Ltd purchased a new position in Elanco Animal Health in the third quarter valued at approximately $34,000. Finally, Quarry LP acquired a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ELAN shares. Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. UBS Group started coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Barclays increased their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $16.71.

Elanco Animal Health Stock Up 0.2 %

Shares of NYSE:ELAN opened at $11.88 on Wednesday. The firm has a market cap of $5.87 billion, a PE ratio of 29.70, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41. The company has a fifty day simple moving average of $12.87 and a 200 day simple moving average of $14.00. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 12-month low of $11.40 and a 12-month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.